Matthew Clements

Dr. Matthew Clements

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in European Urology
Verified
Journal Article
Closed access
MCMatthew Clements
Matthew Clements
TAThomas M. Atkinson
Thomas M. Atkinson
GDGuido M. Dalbagni
Guido M. Dalbagni
YLYuelin Li
Yuelin Li
AVAndrew J. Vickers
Andrew J. Vickers
BBBernard H. Bochner
Bernard H. Bochner

11 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SMShannon McNall
Shannon McNall
KHKailey Hooper
Kailey Hooper
TSTravis Sullivan
Travis Sullivan
KRKimberly Rieger-Christ
Kimberly Rieger-Christ
MCMatthew Clements
Matthew Clements
The landscape of treatment for non-muscle invasive bladder cancer is rapidly changing. A complete and careful transurethral resection is the mainstay of initial treatment and is followed by intravesical therapy in intermediate or high-risk cases. The standard of care is intravesical BCG. Many alternative or additive approaches to this are being explored. We divided this review into three relevant spaces to consider these novel treatment approaches: (1) low-risk disease, for which intravesical therapy is not usually considered, (2) BCG-naïve disease (i.e., considering alternatives to the standard therapy), and (3) BCG-unresponsive disease. We performed a review of published literature and summarized ongoing trials in the United States. Novel approaches that we explored include surgical techniques for resection, alterations in dwell time for intravesical therapy, delivery method and schedule of intravesical therapies, new intravesical therapy agents, and systemic therapies (especially immunotherapy). These are thoroughly outlined throughout this review article, and the numerous modalities being studied demonstrate significant promise for the future treatment of the expanding space of NMIBC.

1 March 2016 in Journal of Endourology
Verified
Journal Article
Closed access
MCMatthew Clements
Matthew Clements
KMKasey Y. Morrison
Kasey Y. Morrison
NSNoah S. Schenkman
Noah S. Schenkman
Introduction/Purpose: Medical simulation offers the advantage of improving resident skill and comfort without impacting patient care. Five years ago, we identified trends in the use of robotic and laparoscopic simulation in 2008 and 2009 at American urology residency training programs. We seek to identify the changes in use of simulators and the presence of formal curricula in the wake of technological advances and changes in graduate medical education. Methods: A`ttendees of the AUA Basic Sciences Course, mostly in their 2nd or 3rd year of residency, were surveyed on the availability and use of laparoscopic/robotic simulators at their program, the presence of a formal curriculum, and a Likert scale questionnaire regarding face and content validity. Results: Over a five year period, the availability of VR robotic simulators increased substantially from 14% to nearly 60% availability in 2013. Despite this increase, the frequency of simulator use remained unchanged (p=0.40) and the reported presence of formal curricula decreased from 41% to 34.8%. There was no significant difference in simulator use between residents in programs with or without laparoscopic/robotic curricula (p=0.95). There was also a decrease in the percentage of residents who felt official laparoscopic curricula (93% to 81%) and simulators (82% to 74%) should be involved in resident education. Conclusions: In the past 5 years, despite evidence supporting benefits from simulator use and increasing availability, self-reported resident use has remained unchanged and the reporting of presence of laparoscopic/robotic curricula has decreased. With more dedicated investment in formal curricula, residency training programs may receive greater returns on their simulator investments, improve resident skills and comfort, and ultimately improve the quality of patient care.

23 December 2019 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
JLJennifer M. Lobo
Jennifer M. Lobo
MCMatthew Clements
Matthew Clements
DBDaniel P. Bitner
Daniel P. Bitner
MMMatthew D. Mikula
Matthew D. Mikula
SNSean W. Noona
Sean W. Noona
TKTracey L. Krupski
Tracey L. Krupski
Purpose: To examine how a multidisciplinary team approach incorporating renal mass biopsy (RMB) into decision making changes the management strategy. Methods: A multidisciplinary team comprised of a radiology proceduralist, a pathologist and urologists convened monthly for renal mass conference with a structured presentation of patient demographics, co-mborbidities, tumor pathology, laboratory and radiographic features. Biopsy protocol was standardized to an 18-gauge core needle biopsy using a sheathed apparatus under renal ultrasound guidance. Biopsy diagnostic rate, and concordance with nephrectomy specimens were summarized. Descriptive statistics were used to evaluate influence of RMB on management decisions. Results: A total of 83 patients with a ≤4 cm mass were discussed, and 66% of patients underwent RMB. Of those, 87% were diagnostic with 9% of core biopsies showing benign pathology. Active surveillance (AS) was recommended for 34% of patients with biopsy data as compared to 64% of those without biopsy. Ablation was recommended for 38% of the biopsy cohort compared to 7% without biopsy. Partial nephrectomy rates were similar for both cohorts, approximately 17% and 22%, respectively. Our complication rate was 1.5%, with only 1 Clavien-Dindo Grade 2 complication. Histology was concordant in 93% of patients that ultimately underwent partial nephrectomy after biopsy. Conclusions: Over half of our SRM patients underwent a RMB that provided a diagnosis in 85% of cases. RMB aided in shared decision making by providing insight into the biology of renal masses, which helps to guide multidisciplinary management and consideration of nephron sparing options.

1 May 2023 in Journal of Urology
Verified
Journal Article
Closed access
MCMatthew Clements
Matthew Clements
BBBenjamin B. Beech
Benjamin B. Beech
TAThomas M. Atkinson
Thomas M. Atkinson
GDGuido M. Dalbagni
Guido M. Dalbagni
YLYuelin Li
Yuelin Li
BBBernard H. Bochner
Bernard H. Bochner
Purpose:To compare health-related quality of life (HRQOL) using a broad range of validated measures in patients randomized to robotic-assisted radical cystectomy (RARC) versus open radical cystecto...

1 May 2014 in Urology
Verified
Journal Article
Closed access
MCMatthew Clements
Matthew Clements
DCDavid J. Chalmers
David J. Chalmers
MMMariana L. Meyers
Mariana L. Meyers
VVVijaya M. Vemulakonda
Vijaya M. Vemulakonda